Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

William G. Wierda, MD, PhD, J. Castro, MD, R. Aguillon, MD, A. Jalayer, RN, J. McMannis, PhD, C. Prussak, PhD, M. Keating, MB, BS, T. Kipps, MD, PhD

Blood (2007) 110 (11): 2040.

https://doi.org/10.1182/blood.V110.11.2040.2040

Published: 2007

Journal Articles

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, S. Faderl, MD, A. Ferrajoli, MD, G. Garcia-Manero, MD, J. Burger, MD, E. Schlette, MD, L. Abruzzo, MD, PhD, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 2065.

https://doi.org/10.1182/blood.V110.11.2065.2065

Published: 2007

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 628.

https://doi.org/10.1182/blood.V110.11.628.628

Published: 2007

Journal Articles

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

William G. Wierda, MD, PhD, S. Mulligan, MD, B. Shelvin, L. Belov, PhD, L. Rassenti, PhD, T. Kipps, MD, PhD, S. Lerner, MS, M. Thomas, PhD, H. Kantarjian, MD, M. Keating, MB, BS

Blood (2005) 106 (11): 2944.

https://doi.org/10.1182/blood.V106.11.2944.2944

Published: 2005

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

NARROW

A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Email alerts

ASH Publications

American Society of Hematology

A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only